Skip to main content

Physician Search

 


Displaying 1 - 2 of 2

Testing Pembrolizumab with Existing Cancer Therapy in Patients with Evidence of Residual Chronic Myelogenous Leukemia

Leukemia

This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, nilotinib, or bosutinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the bodys immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dasatinib, imatinib mesylate, nilotinib, and bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, nilotinib, or bosutinib may work better in treating patients with chronic myeloid leukemia compared to dasatinib, imatinib mesylate, nilotinib, or bosutinib alone.
Leukemia
II
Mohan, Sanjay
NCT03516279
ECOGHEMEA9171

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant / Intolerant Ph + Chronic Myeloid Leukemia

Multiple Cancer Types

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R / I CML), to preliminary estimate the safety and tolerability and efficacy, and to evaluate the PK of bosutinib in this patient population.
Pediatric Leukemia, Pediatrics
I/II
Zarnegar-Lumley, Sara
NCT04258943
COGAAML1921